Juvenile myoclonic epilepsy (JME) …

Fernando Cendes MD PhD

Epilepsy & Seizures

Updated 06.11.2024
Released 10.18.1993
Expires For CME 06.11.2027

Juvenile myoclonic epilepsy

Author: Fernando Cendes MD PhD

See Contributor Disclosures

Editor: Jerome Engel Jr MD PhD

Juvenile myoclonic epilepsy

In This Article

Quick Link

Introduction

Overview

In this updated article, the author discusses evidence concerning brain network damage and dysfunction, genetic factors, as well as prognosis and antiseizure medication treatment in juvenile myoclonic epilepsy.

Key points

	• Juvenile myoclonic epilepsy is a form of idiopathic generalized epilepsy, also defined as genetic generalized epilepsy. It is characterized by (a) myoclonic seizures (cardinal symptom) that are most frequent in the early morning and (b) generalized tonic-clonic seizures. Typical absence seizures may also occur, but these are infrequent and short and are often ignored by the patient.
	• The differential diagnosis includes other types of genetic generalized epilepsies, juvenile absence epilepsy, and generalized tonic-clonic seizures alone (formerly known as generalized tonic-clonic seizures on awakening).
	• Although juvenile myoclonic epilepsy has been considered a long-lasting condition, with frequent seizure relapses after withdrawal of medication, studies have shown that a proportion of patients become seizure-free off medication.
	• Sodium valproate is the most effective medicine; however, the high risk of fetal malformations and other side effects limit its use in young women. Lamotrigine, levetiracetam, and brivaracetam are good alternatives, but lamotrigine may exacerbate myoclonus. Benzodiazepines may have an adjunctive role, in particular clobazam or clonazepam.
	• Lifestyle advice is an integral part of the treatment of juvenile myoclonic epilepsy. Patients should avoid sleep deprivation and drinking alcohol.

Historical note and terminology

Juvenile myoclonic epilepsy was first reported in France by Herpin (45). The terminology was variable until Janz and his colleagues in Germany reported 47 cases and proposed the name "impulsive petit mal" as a clinically definable epileptic syndrome (51; 50). The syndrome was later called juvenile myoclonic epilepsy (of Janz) in the English-speaking literature (02; 21; 18).

Juvenile myoclonic epilepsy is one of the most common “electroclinical” syndromes within the idiopathic generalized epilepsies (78; 27; 46). There are four primary and well‐established epilepsy syndromes within the idiopathic generalized epilepsies: childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and generalized tonic-clonic seizures alone (formerly known as generalized tonic-clonic seizures on awakening) (78; 46). There has been a debate as to whether to define this group of syndromes as idiopathic generalized epilepsies or genetic generalized epilepsies as both terms have pros and cons (07; 78). The ILAE Commission on Classification and Terminology decided to keep both terms to define this group of generalized epilepsies (78; 46).

Clinical manifestations

Presentation and course

Juvenile myoclonic epilepsy typically appears in the second decade. The age of onset ranges from 8 to 24 years, with peak onset between 12 and 18 years (21). It is characterized by myoclonic seizures, associated at times with generalized tonic-clonic seizures or absence seizures.

A detailed medical history with a specific focus on seizure types, age at onset, timing, and triggers is fundamental for the diagnosis (27). Comorbidities and family history are also important. The EEG can provide valuable information for the diagnosis, including specific idiopathic generalized epilepsy syndromes, and, therefore, contributes to the best course of treatment and management.

The cardinal seizure type is that of myoclonic jerks characterized by sudden, brief, bilaterally symmetrical and synchronous muscle contractions. The intermittent and involuntary shocklike contractions ("secousse") affect mainly the shoulder and upper extremities; much less commonly, the lower extremities or the entire body may also be involved. Myoclonic seizures may occur either singly or in clusters (02; 48). Objects may be thrown as a result of jerks, or, rarely, patients may fall. Consciousness remains unimpaired during myoclonic seizures, even if they occur in series or in myoclonic status epilepticus (49).

Because the jerks in juvenile myoclonic epilepsy are brief, without impairment of awareness, and take place in the morning soon after awakening, they are often interpreted as "nervousness" or "clumsiness" until generalized convulsions occur (25). Many patients ignore mild events and are unaware that they are abnormal (88). Therefore, physicians need to ask specifically about jerks early in the morning, which in association with the characteristic EEG pattern, makes it difficult to miss this diagnosis.

Generalized tonic-clonic seizures appear after the onset of myoclonic seizures in most cases (02). The average interval between the first myoclonic seizures and the beginning of tonic-clonic seizures is 3.3 years (48). A convulsive seizure may begin with a series of myoclonic jerks of increasing intensity, followed by generalized myoclonus and then by generalized tonic-clonic seizures. This characteristic picture has been described as "myoclonic grand mal," "impulsive grand mal," and "clonic-tonic-clonic seizures" (48).

Both the myoclonic seizures and generalized tonic-clonic seizures have a special circadian pattern, ie, they frequently occur on or soon after awakening, either from all-night sleep or from a nap (02). The myoclonic and generalized tonic-clonic seizures are frequently precipitated by early awakening, sleep deprivation, emotional stress, alcohol consumption, recreational drug use, or photic provocation (25; 49). Occasionally, they may also occur sporadically during the daytime, or when the patients are tired and relaxed. Photosensitivity occurs in approximately one third of the patients (02; 25; 34; 27). Seizure precipitation by complex neuropsychological tasks, especially when they require some kind of motor action ("praxis-induction"), has been shown to be associated with juvenile myoclonic epilepsy in up to half of the patients and may be associated with less favorable response to pharmacotherapy (62; 92). As peri-oral reflex myoclonias elicited by talking and reading are also frequent in this syndrome (63), the presence of some reflex epileptic traits seems to be one of its characteristics (07; 88).

Absence seizures, usually of typical variants, occur in 15% to 30% of patients and begin at a mean age of 11.5 years (02; 21), although these are infrequent and shorter than in childhood absence epilepsy or in juvenile absence epilepsy, and frequently go unnoticed by patients and family members (88).

Prognosis and complications

Juvenile myoclonic epilepsy does not remit spontaneously in most patients (46). Studies have shown that relapse rate after discontinuation of antiseizure medications is high, varying from 78% to 90% (48; 79; 82). However, some studies indicate that lifelong therapy may not be necessary for all patients (73). A population-based study showed that one third of patients did not require antiseizure medication treatment 25 years after onset of seizures, with 17% being free of all seizure types and 13% with only myoclonus (12). Another study showed that after a mean follow up of 45 years, 59% of patients were seizure-free for five years or more, and 28% of those were off medication (81). Hofler and colleagues showed that after a period of up to 36 years, 62% of patients with juvenile myoclonic epilepsy were free of all types of seizures for more than one year, 53% for more than two years with antiseizure medication, and 9% of patients were seizure-free for more than two years without medication (47). Pietrafusa and colleagues evaluated the long-term prognosis in 61 patients with juvenile myoclonic epilepsy and found that 40 (65%) had a 5-year terminal remission with a mean age at last seizure of 27.4 years (74). After withdrawal of antiseizure medications in 13 of these seizure-free patients, six had seizure recurrence, whereas seven remained seizure-free. Interestingly, the mean age at antiseizure medications withdrawal was longer in the subgroup of seven patients who remained seizure-free (21 vs. 35.7 years, p < 0.05) (74). Taken together, these long-term follow up studies indicate that the longer the patients are seizure-free on antiseizure medication, the more likely it is for them to continue seizure-free after medication withdrawal (12; 81; 47; 35; 74).

The presence of absence seizures and high frequency of generalized tonic-clonic seizures at onset were associated with poorer prognosis (81; 47; 35; 74). Patients with prolonged epileptiform discharges in ambulatory EEG and psychiatric comorbidities also had a poorer prognosis (09; 91). One study showed that the onset of psychiatric symptoms prior to the onset of epilepsy, photosensitivity, and valproate resistance were the most important factors affecting neuropsychiatric comorbidities in idiopathic generalized epilepsies, including juvenile myoclonic epilepsy (76). A meta-analysis found that psychiatric comorbidities, catamenial epilepsy, focalities on EEG, history of childhood absence epilepsy, family history of epilepsy, status epilepticus, and febrile seizures were independent predictors of pharmacoresistance in juvenile myoclonic epilepsy (82).

Clinical vignette

A 30-year-old woman was referred for consultation in the epilepsy clinic. She had a history of generalized tonic-clonic seizures since the age of 14. Seizures occurred mostly soon after awakening or after stressful moments, particularly when she was very tired or had lack of sleep. She brought a couple of normal EEGs and a normal MRI and said that her previous doctors, including a neurologist, did not know what she had because all the exams were normal. She was using carbamazepine and had taken phenytoin and phenobarbital in the past without good seizure control.

Her neurologic examination was normal, and during the interview she confirmed that she had had myoclonic jerks in the morning, but she never thought that this was relevant. Doctors never asked her about these jerks, which did not bother her much.

She was told that her diagnosis was juvenile myoclonic epilepsy. An EEG after partial sleep deprivation showed typical 4-Hz generalized spike and polyspike-and-slow waves with predominance over the frontal regions.

Because she was overweight and had plans to get pregnant, and the myoclonic jerks were not very frequent, she was prescribed lamotrigine, with a very slow titration up to 300 mg a day. She has been free of generalized tonic-clonic seizures and has had rare early morning myoclonus.

This is a typical history, and it is usually easy to make a diagnosis of juvenile myoclonic epilepsy. It is still often misdiagnosed and mistreated by many physicians, even though it is one of the most common forms of epilepsy in young adults. Early morning myoclonic jerks are an important feature and should always be asked of patients with a history of generalized tonic-clonic seizures.

Biological basis

Etiology and pathogenesis

Juvenile myoclonic epilepsy is an electroclinical epilepsy syndrome with a strong genetic component following a complex pattern of inheritance, with a polygenic basis and an environmental contribution (99; 88; 53; 06). Not a single case associated with organic brain pathology has been reported, although a history of febrile or isolated seizures in childhood can be obtained in a minority of cases (48; 49; 46).

Up to 50% of patients have first- and second-degree relatives with epileptic seizures, and 80% of symptomatic and 6% to 16% of asymptomatic siblings have diffuse 4- to 6-Hz polyspike-and-wave complexes on their EEG (61).

The concordance rate for monozygotic twins is 0.7 to 1.0, whereas that for dizygotic twins is the same as in siblings (38). Despite long and intense genetic research, the genetics of the syndrome are not fully clarified. A polygenic mode of inheritance is the more likely cause as the different reflex epileptic traits that are frequent parts of the phenotype are also genetically determined. A relationship appears to exist between juvenile myoclonic epilepsy and other age-related genetic generalized epilepsies such as childhood absence epilepsy, epilepsy with generalized tonic-clonic seizures alone, and early childhood myoclonic epilepsy because more than one phenotype may exist in the same family (99).

Several genes predisposing to juvenile myoclonic epilepsy have been identified over the last decades, although results are not always replicated in different studies indicating a high genetic heterogeneity (28; 43; 84; 41). Among these genes, mutations in genes encoding for subunits of the gamma-aminobutyric acid (GABA)A receptor and in the Myoclonin1/EFHC1 gene have been reported in patients with juvenile myoclonic epilepsy (20; 23; 53; 84; 58). EFHC1 is involved in the regulation of cell division and with the process of neuronal radial migration during embryogenesis (19; 23). However, the gene-disease relationship between EFHC1 and juvenile myoclonic epilepsy is still unclear (37). Thus, the inclusion of EFHC1 in gene panels for genetic testing should be limited to research purposes (19; 37).

Conventional neuroimaging evaluation is normal (46); however, studies using quantitative structural and functional neuroimaging have shown subtle, but consistent, abnormalities in patients with juvenile myoclonic epilepsies that help to better understand the pathophysiology of this disease (93; 97; 24; 29; 26; 10; 96; 70; 72).

Wandschneider and colleagues used quantitative postprocessing techniques of high-resolution structural MRIs to measure the cortical surface curvature, morphology, and the geodesic distance, a surrogate marker of cortico-cortical connectivity in patients with juvenile myoclonic epilepsy and their unaffected siblings (96). They found that patients and siblings had increased cortical curvature and surface, as well as changes in geodesic distance that were more prominent in prefrontal and cingulate cortices, which are areas undergoing late maturation. Their results indicate that these MRI biomarkers of brain development and connectivity are likely heritable and, thus, relate to the underlying disease neurobiology. However, cortical thinning in frontocentral and occipital cortices occurred only in patients with juvenile myoclonic epilepsy but not in their siblings, probably representing a marker of seizures as opposed to the epileptogenic pathophysiology (96).

There has been growing neuroimaging evidence for a thalamic-cortico-frontal network dysfunction in juvenile myoclonic epilepsies (93; 24; 29; 26). These abnormalities do not appear to be secondary to seizures and may be genetically determined (56; 97). Indeed, unaffected siblings of juvenile myoclonic epilepsy patients showed abnormal fMRI co-activation in the primary motor cortex and supplementary motor area, as well as abnormal functional connectivity between motor and prefrontal cognitive networks, similarly as in juvenile myoclonic epilepsy patients (95).

Microstructural white matter and gray matter abnormalities were present in patients with new-onset juvenile myoclonic epilepsy using diffusion tensor imaging (DTI), indicating these abnormalities exist since the beginning of the disease (26). In addition, there is evidence for a network dysfunction, with hyperconnectivity involving primary motor, parietal, and subcortical regions that correlate with cognitive task performance (11).

Studies have shown that patients with all subtypes of genetic generalized epilepsies present clear reductions in functional connectivity within the default mode network, which includes the precuneus, posterior cingulate cortex, the medial prefrontal cortex, parietal cortex, and inferior temporal cortex (72). Functional connectivity changes in the default mode network may be related to the cognitive deficits, anxiety and depression in patients with juvenile myoclonic epilepsies and other idiopathic generalized epilepsies (31).

Differential diagnosis

Confusing conditions

Myoclonic seizures occur in patients with other idiopathic generalized epilepsies, such as the juvenile absence epilepsy and epilepsy with generalized tonic-clonic seizures alone, but are mild and have no particular circadian distribution and are not the most prominent features of these syndromes (27).

In epilepsy with eyelid myoclonia syndrome, also known in the past as Jeavons syndrome, there are frequent episodes of fast (greater than 4 Hz) rhythmic jerks of the eyelids and upward deviation of the eyeballs, with or without absence seizures (27). Onset after 10 years of age, good response to antiseizure medication, and preserved cognitive performance suggest a continuum between juvenile myoclonic epilepsy and epilepsy with eyelid myoclonia (32). Early-onset epilepsy with eyelid myoclonia syndrome is usually pharmacoresistant and associated with intellectual disability, heliotropism, and self-induced seizures by hand waving (sunflower syndrome) (32).

Lennox-Gastaut syndrome, epilepsy with myoclonic-astatic seizures, and epilepsy with myoclonic absences begin in childhood rather than adolescence and are associated with more frequent seizures and cognitive impairment. In the latter two, the myoclonic seizures usually involve the face and are associated with absences, whereas consciousness is not impaired during myoclonic seizures of juvenile myoclonic epilepsy (25; 88).

Postanoxic or posthypoxic myoclonus can be acute or chronic. Acute posthypoxic myoclonus occurs within hours of the hypoxia while the patient is still unconscious, has a generalized multifocal distribution, is elicited by external stimulus or movements, and commonly demonstrates generalized EEG abnormalities, including epileptiform discharges, but acute posthypoxic myoclonus may also be of subcortical nature (nonepileptic myoclonus). Chronic posthypoxic myoclonus, or Lance-Adams syndrome, develops after the patient recovers consciousness and presents as multifocal action myoclonus (42).

Familial adult myoclonic epilepsy or adult myoclonic epilepsy with cortical tremor is associated with prominent cortical tremor and may mimic juvenile myoclonic epilepsy (40).

In progressive myoclonic epilepsies, nonepileptic multifocal myoclonus and epileptic myoclonus often coexist and are clinically different from those in juvenile myoclonic epilepsy. Progressive neurologic deterioration, dementia, action myoclonus, and ataxia are important features in progressive myoclonic epilepsies and never occur in juvenile myoclonic epilepsy (69).

Diagnostic workup

Because the jerks in juvenile myoclonic epilepsy are brief, without loss of consciousness, and take place in the morning soon after awakening, they are often interpreted as "nervousness" or "clumsiness" until generalized convulsions occur (25). Many patients ignore mild events and are unaware that they are abnormal (88).

The EEG background activity is normal during wakefulness and sleep, except in case of antiseizure medication intoxication or inadequate treatment.

Seventy-four percent of patients have epileptiform interictal EEG patterns (67). Typical interictal abnormalities consist of brief (1 to 3 seconds) 3- to 6-Hz generalized discharges of spike and polyspike-and-slow waves that are usually asymptomatic, and sometimes may appear asymmetrical or with pseudo focalities (57). Focal EEG features are relatively common and may contribute to misdiagnosis of juvenile myoclonic epilepsy as focal epilepsy; however, these focalities do not influence treatment response (80; 52). Classical 3-Hz spike-and-wave complexes or 3-Hz polyspike-and-wave complexes characteristic of typical absence seizures may occur in some teenagers.

The ictal EEG is characterized by 10- to 16-Hz medium-high amplitude spikes followed by irregular slow waves. The number of spikes ranges from 5 to 20 per episode and correlates with the intensity rather than the duration of each seizure (50).

Provocative measures, such as photic stimulation and sleep deprivation, can help elicit the characteristic EEG abnormalities. Recording during the process of awakening may be necessary for the diagnosis (48). Sleep deprivation is very effective in precipitating seizures. Praxis-induction is found by neuropsychological testing during EEG (62), and perioral reflex myoclonias, unless observed during the interview with the patient, require a video-EEG investigation that includes reading aloud and free talking (63). Polyspike-and-wave discharges are seen more frequently after nocturnal awakening than after morning awakening (48). The incidence of photosensitivity has been reported to be as high as 30.5% (48).

Neurologic examination and neuroimaging studies are normal in this syndrome. When the clinical presentation and EEGs are typical for juvenile myoclonic epilepsy, imaging is not required for clinical management. However, MRI should be considered if atypical features or pharmacoresistant seizures are present, or if there is persistent focal slowing on EEG (46).

One study showed unrelated or nonspecific MRI abnormalities in up to 24% of juvenile myoclonic epilepsy patients (08). There was a higher proportion of EEG focalities in patients with abnormal MRI, which were, in most part, concordant with the location of the MRI findings (08). As mentioned previously, these findings may predict poorer response to antiseizure medications (82).

Management

Both medical treatment and counseling are important in the management of juvenile myoclonic epilepsy. Monotherapy with sodium valproate is the most effective in controlling myoclonic, generalized tonic-clonic, and absence seizures (36). Due to its reduced serum fluctuations and single daily dosage, divalproex sodium extended-release formulation may significantly improve tremor, weight gain, and gastrointestinal complaints while maintaining similar seizure control as valproate traditional formulation (55). Low doses of valproate (500 to 1000 mg) may be sufficient for initial treatment in juvenile myoclonic epilepsy (44). However, up to 30% of patients with juvenile myoclonic epilepsy do not respond to valproate and other monotherapies (01).

However, the significantly higher risk of fetal malformations (90) and of worse cognitive outcome as well as higher frequency of autism spectrum disorder and attention-deficit or hyperactivity disorder in children born to women who used valproate limit its use in young women (17; 98). On the other hand, studies suggest that avoiding valproate might be associated with unsatisfactory seizure control in women with juvenile myoclonic epilepsy who are of childbearing potential (15; 36). In women of childbearing potential, levetiracetam and lamotrigine should represent the first-choice treatment (01; 04; 66).

Levetiracetam is a good alternative to valproate, particularly when lamotrigine exacerbates myoclonus (87). One study showed a lower retention rate for levetiracetam than valproate due to poorer seizure control during long-term follow-up, but patients with levetiracetam achieved more myoclonic seizure freedom than those with valproate (77). There is some evidence that levetiracetam may have better efficacy than lamotrigine in monotherapy for patients with juvenile myoclonic epilepsy (64). However, psychiatric adverse effects are common with levetiracetam and may lead to treatment discontinuation; it should be avoided in patients with antecedent of depression (54). An alternative to levetiracetam is brivaracetam. Brivaracetam is well tolerated and has shown a good efficacy for treating patients with juvenile myoclonic epilepsy and other forms of genetic generalized epilepsies (85; 30). The occurrence of behavioral adverse events appears to be less frequent with brivaracetam than with levetiracetam, and the switch between these two medications can be made easily (85).

Lamotrigine is a good choice for treating patients with juvenile myoclonic epilepsy, particularly in those with psychiatric comorbidities, but it may exacerbate myoclonus (60). Clonazepam is a useful add-on therapy for myoclonus and can be used in combination with lamotrigine to avoid its promyoclonic effects. The combination of lamotrigine and valproate may be an alternative for patients who fail seizure control with monotherapy. One study showed that the combination of lamotrigine and valproate was successful in 69% as compared to 9% with all other combinations in patients who failed to respond to valproate in monotherapy (03). In addition, only one of 24 (4%) patients became seizure-free after failing the valproate and lamotrigine combination (03).

Topiramate and zonisamide may be an alternative for some patients who do not tolerate valproate, particularly patients with severe weight gain due to valproate (71; 09).

Benzodiazepines may have an adjunctive effect for short periods and are sometimes good for intermittent use in specific stressful situations. Clonazepam may be beneficial for controlling myoclonic seizures but not the generalized tonic-clonic seizures. Complete elimination of myoclonic seizures could cause additional disability by depriving some patients of the warning jerks that herald the onset of generalized tonic-clonic seizures (68).

Seizures are usually precipitated by fatigue, noncompliance, stress, sleep deprivation, and alcohol consumption. Successful treatment is contingent on acceptance of appropriate limitations on lifestyle. Up to one third of patients with juvenile myoclonic epilepsy may have difficulty in treating seizures, and the presence of absence seizures, psychiatric comorbidities, earlier age at seizure onset, and praxis-induced seizures appears to indicate poorer outcome (83).

Outcomes

Juvenile myoclonic epilepsy is a life-long condition, and although a significant proportion of patients remain seizure-free on medication, 70% to 90% will have relapse seizures with the withdrawal of antiseizure medication (48; 79; 12; 81; 94; 35; 36).

Complete remission of generalized tonic-clonic seizures under antiseizure medication significantly increased the chance for complete seizure freedom, and the occurrence of EEG photoparoxysmal responses significantly increases the risk of seizure recurrence after antiseizure medication discontinuation (33). The presence of absence seizures is an independent predictor of poorer outcome (05; 81; 35).

In a meta-analysis, Stevelink and colleagues estimated that 35% of patients with juvenile myoclonic epilepsy were pharmacoresistant; however, the proportion of patients with pharmacoresistance varied greatly among the studies analyzed (83). In an epidemiologic study, Gesche and colleagues estimated that 12.1% of patients with genetic generalized epilepsies were pharmacoresistant, with an average burden of seizures of 2.2 generalized tonic-clonic seizures per year (35). Although the overall frequency of seizure freedom was high, only 18.6% of the patients achieved seizure freedom with acceptable side effects at the first treatment trial in a cohort of 328 adult patients with idiopathic generalized epilepsy (36).

In the long-term follow-up, most patients with juvenile myoclonic epilepsy have a fluctuating pattern, with variable intervals of seizure control and seizure relapse that may subside over time (31; 16).

Intelligence usually remains normal in patients with juvenile myoclonic epilepsy (48; 75). However, associated immature personality, emotional instability, inadequate social adjustment, impulsivity, depression, and personality disorders occur frequently irrespective of seizure control (97; 59). Together with higher seizure frequency, impulsive behavior correlates with worse social adjustment (65). In one study, praxis-induced seizures were more common in males, and patients with reflex traits presented higher rates of persistent myoclonia and more frequent psychiatric comorbidities (14). Patients who do not respond well to antiseizure medications are more likely to have depressive and anxiety symptoms than those free of seizures (31).

References

01: Ascoli M, Mastroianni G, Gasparini S, et al. Diagnostic and therapeutic approach to drug-resistant juvenile myoclonic epilepsy. Expert Rev Neurother 2021;21(11):1265-73. PMID 33993822
02: Asconape J, Penry JK. Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 1984;25:108-14. PMID 6420145
03: Baheti N, Rathore C, Bansal AR, et al. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: valproate resistance may not be the end of the road. Seizure 2021;92:112-7. PMID 34496330
04: Ballvé A, Salas-Puig J, Quintana M, et al. Levetiracetam as first-line monotherapy for idiopathic generalized epilepsy in women. Acta Neurol Scand 2021;143(4):407-12. PMID 33452703
05: Baykan B, Martínez-Juárez IE, Altindag EA, Camfield CS, Camfield PR. Lifetime prognosis of juvenile myoclonic epilepsy. Epilepsy Behav 2013;28 Suppl 1:S18-24. PMID 23756474
06: Baykan B, Wolf P. Juvenile myoclonic epilepsy as a spectrum disorder: a focused review. Seizure 2017;49:36-41. PMID 28544889
07: Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-85. PMID 20196795
08: Betting LE, Mory SB, Lopes-Cendes I, et al. MRI reveals structural abnormalities in patients with idiopathic generalized epilepsy. Neurology 2006;67(5):848-52. PMID 16966549
09: Brodie MJ. Modern management of juvenile myoclonic epilepsy. Expert Rev Neurother 2016;16(6):681-8. PMID 27082040
10: Caciagli L, Wandschneider B, Xiao F, et al. Abnormal hippocampal structure and function in juvenile myoclonic epilepsy and unaffected siblings. Brain 2019;142(9):2670-87. PMID 31365054
11: Caeyenberghs K, Powell HW, Thomas RH, et al. Hyperconnectivity in juvenile myoclonic epilepsy: a network analysis. Neuroimage Clin 2014;7:98-104. PMID 25610771
12: Camfield CS, Camfield PR. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study. Neurology 2009;73(13):1041-5. PMID 19786695
13: Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav 2013;28 Suppl 1:S15-7. PMID 23756473
14: Carvalho KC, Uchida CG, Guaranha MS, Guilhoto LM, Wolf P, Yacubian EM. Cognitive performance in juvenile myoclonic epilepsy patients with specific endophenotypes. Seizure 2016;40:33-41. PMID 27343727
15: Cerulli Irelli E, Morano A, Cocchi E, et al. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: Implications on seizure outcome. Epilepsia 2020a;61(1):107-114. PMID 31828782
16: Cerulli Irelli E, Morano A, Barone FA, et al. Persistent treatment resistance in genetic generalized epilepsy: A long-term outcome study in a tertiary epilepsy center. Epilepsia 2020b;61(11):2452-60. PMID 33345323
17: Cohen MJ, Meador KJ, May R, et al. Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: the NEAD prospective observational study. Epilepsy Behav 2019;92:154-64. PMID 30660966
18: Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99. PMID 2502382
19: Conte FF, Ribeiro PA, Marchesini RB, et al. Expression profile and distribution of Efhc1 gene transcript during rodent brain development. J Mol Neurosci 2009;39(1-2):69-77. PMID 19191033
20: Cossette P. Channelopathies and juvenile myoclonic epilepsy. Epilepsia 2010;51 Suppl 1:30-2. PMID 20331709
21: Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-94. PMID 6422321
22: Delgado-Escueta AV, Greenberg DA, et al. Mapping the gene for juvenile myoclonic epilepsy. Epilepsia 1989;30:S8-18. PMID 2570690
23: de Nijs L, Wolkoff N, Coumans B, Delgado-Escueta AV, Grisar T, Lakaye B. Mutations of EFHC1, linked to juvenile myoclonic epilepsy, disrupt radial and tangential migrations during brain development. Hum Mol Genet 2012;21(23):5106-17. PMID 22926142
24: de Oliveira MS, Betting LE, Mory SB, Cendes F, Castellano G. Texture analysis of magnetic resonance images of patients with juvenile myoclonic epilepsy. Epilepsy Behav 2013;27(1):22-8. PMID 23357730
25: Dreifuss FE. Juvenile myoclonic epilepsy: characteristics of a primary generalized epilepsy. Epilepsia 1989;30:S1-7. PMID 2506006
26: Ekmekci B, Bulut HT, Gümüştaş F, Yıldırım A, Kuştepe A. The relationship between white matter abnormalities and cognitive functions in new-onset juvenile myoclonic epilepsy. Epilepsy Behav 2016;62:166-70. PMID 27484748
27: Elmali AD, Auvin S, Bast T, Rubboli G, Koutroumanidis M. How to diagnose and classify idiopathic (genetic) generalized epilepsies. Epileptic Disord 2020;22(4):399-420. PMID 32782228
28: EPICURE Consortium, Leu C, de Kovel CG, et al. Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies. Epilepsia 2012;53(2):308-18. PMID 22242659
29: Focke NK, Diederich C, Helms G, Nitsche MA, Lerche H, Paulus W. Idiopathic-generalized epilepsy shows profound white matter diffusion-tensor imaging alterations. Hum Brain Mapp 2014;35(7):3332-42. PMID 25050427
30: Fonseca E, Guzmán L, Quintana M, et al. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav 2020;102:106657. PMID 31731108
31: Garcia DD, Polydoro MS, Alvim MKM, et al. Anxiety and depression symptoms disrupt resting state connectivity in patients with genetic generalized epilepsies. Epilepsia 2019;60(4):679-88. PMID 30854641
32: Gauer L, Baer S, Valenti-Hirsch MP, De Saint-Martin A, Hirsch E. Drug-resistant generalized epilepsies: revisiting the frontiers of idiopathic generalized epilepsies. Rev Neurol (Paris) 2024;180(4):290-7. PMID 38508955
33: Geithner J, Schneider F, Wang Z, et al. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up. Epilepsia 2012;53(8):1379-86. PMID 22686598
34: Genton P, Thomas P, Kasteleijn-Nolst Trenité DG, Medina MT, Salas-Puig J. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy Behav 2013;28(Suppl 1):S8-14. PMID 23756488
35: Gesche J, Christensen J, Hjalgrim H, Rubboli G, Beier CP. Epidemiology and outcome of idiopathic generalized epilepsy in adults. Eur J Neurol 2020a;27(4):676-84. PMID 31838768
36: Gesche J, Hjalgrim H, Rubboli G, Beier CP. Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology 2020b;95(18):e2519-28. PMID 32817177
37: Gonsales MC, Ribeiro PA, Betting LE, et al. Revisiting the clinical impact of variants in EFHC1 in patients with different phenotypes of genetic generalized epilepsy. Epilepsy Behav 2020;112:107469. PMID 33181902
38: Greenberg DA, Delgado-Escueta AV, Maldonado HM, Widelitz H. Segregation analysis of juvenile myoclonic epilepsy. Genet Epidemiol 1988;5:81-94. PMID 3136050
39: Grunewald RA, Chroni E, Panayiotopoulos CP. Delayed diagnosis of juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1992;55:497-9. PMID 1619419
40: Guerrini R, Bonanni P, Patrignani A, et al. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: A newly recognized epilepsy syndrome with linkage to chromosome 2p11.1-q12.2. Brain 2001;124(Pt 12):2459-75. PMID 11701600
41: Guerrini R, Marini C, Barba C. Generalized epilepsies. Handb Clin Neurol 2019;161:3-15. PMID 31307608
42: Gupta HV, Caviness JN. Post-hypoxic myoclonus: current concepts, neurophysiology, and treatment. Tremor Other Hyperkinet Mov (N Y) 2016;6:409. PMID 27708982
43: Heinzen EL, Depondt C, Cavalleri GL, et al. Exome sequencing followed by large-scale genotyping fails to identify single rare variants of large effect in idiopathic generalized epilepsy. Am J Hum Genet 2012;91(2):293-302. PMID 22863189
44: Hernández-Vanegas LE, Jara-Prado A, Ochoa A, et al. High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: going from low to high. Epilepsy Behav 2016;61:34-40. PMID 27300146
45: Herpin TH. Des accès incomplets d’épilepsie. Paris: Baillière, 1867.
46: Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1475-99. PMID 35503716
47: Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Seizure outcome in 175 patients with juvenile myoclonic epilepsy - a long-term observational study. Epilepsy Res 2014;108(10):1817-24. PMID 22863189
48: Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985;52:449-59. PMID 3936330
49: Janz D. Juvenile myoclonic epilepsy. Cleve Clin J Med 1989;56:S23-33. PMID 2498010
50: Janz D, Christian W. Impulsiv - petit mal. Deutsche Zeitschrift für Nervenheilkunde 1957;176:346-86.
51: Janz D, Matthes A. Die Propulsiv - petit mal - Epilepsie. New York: S Karger, 1955.
52: Japaridze G, Kasradze S, Lomidze G, et al. Focal EEG features and therapeutic response in patients with juvenile absence and myoclonic epilepsy. Clin Neurophysiol 2016;127(2):1182-7. PMID 26712538
53: Johannesen K, Marini C, Pfeffer S, et al. Phenotypic spectrum of GABRA1: from generalized epilepsies to severe epileptic encephalopathies. Neurology 2016;13;87(11):1140-51. PMID 27521439
54: Josephson CB, Engbers JDT, Jette N, et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurol 2019;76(4):440-6. PMID 30688969
55: Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia 2013;54(1):28-35. PMID 23190215
56: Liu M, Concha L, Beaulieu C, Gross DW. Distinct white matter abnormalities in different idiopathic generalized epilepsy syndromes. Epilepsia 2011;52(12):2267-75. PMID 22092238
57: Lombroso CT. Consistent EEG focalities detected in subjects with primary generalized epilepsies monitored for two decades. Epilepsia 1997;38(7):797-812. PMID 9579907
58: Loucks CM, Park K, Walker DS, et al. EFHC1, implicated in juvenile myoclonic epilepsy, functions at the cilium and synapse to modulate dopamine signaling. Elife 2019;8. PMID 30810526
59: Mangaard S, Gesche J, Delcomyn L, Beier CP. The burden of disease of idiopathic/genetic generalized epilepsy - A nationwide online survey. Epilepsy Behav 2021;123:108232. PMID 34416520
60: Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol 2011;13(4):355-70. PMID 21494841
61: Martínez-Juárez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain 2006;129:1269-80. PMID 16520331
62: Matsuoka H, Takahashi T, Sasaki M, et al. Neuropsychological EEG activation in patients with epilepsy. Brain 2000;123:318-30. PMID 10648439
63: Mayer T, Schroeder F, Wolf P. Reflex epileptic traits in juvenile myoclonic epilepsy. Epilepsia 2001;42(suppl 2):176-7.
64: Milano C, Turco F, Pizzanelli C, et al. Response to levetiracetam or lamotrigine in subjects with juvenile myoclonic epilepsy previously treated with valproic acid: a single center retrospective study. Epilepsy Behav 2021;115:107706. PMID 33423017
65: Moschetta S, Valente KD. Impulsivity and seizure frequency, but not cognitive deficits, impact social adjustment in patients with juvenile myoclonic epilepsy. Epilepsia 2013;54(5):866-70. PMID 23621878
66: Mostacci B, Ranzato F, Giuliano L, et al. Alternatives to valproate in girls and women of childbearing potential with idiopathic generalized epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE). Seizure 2021;85:26-38. PMID 33418162
67: Obeid T, Panayiotopoulos CP. Juvenile myoclonic epilepsy: a study in Saudi Arabia. Epilepsia 1988;29:280-2. PMID 3131135
68: Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia 1989;30:603-6. PMID 2507306
69: Orsini A, Valetto A, Bertini V, et al. The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy. Seizure 2019;71:247-57. PMID 31476531
70: Öztürk Z, Güneş A, Karalok ZS. Subcortical gray matter changes in pediatric patients with new-onset juvenile myoclonic epilepsy. Epilepsy Behav 2020;104(Pt A):106860. PMID 31935646
71: Park KM, Kim SH, Nho SK, et al. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci 2013;20(8):1079-82. PMID 23673144
72: Parsons N, Bowden SC, Vogrin S, D'Souza WJ. Default mode network dysfunction in idiopathic generalised epilepsy. Epilepsy Res 2020;159:106254. PMID 31862479
73: Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia 1989;30:S19-23. PMID 2506007
74: Pietrafusa N, La Neve A, de Palma L, et al. Juvenile myoclonic epilepsy: Long-term prognosis and risk factors. Brain Dev 2021;43(6):688-97. PMID 33781581
75: Raatikainen M, Kälviäinen R, Jutila L, Äikiä M. Cognitive functioning in new-onset juvenile myoclonic epilepsy. Epilepsy Behav 2020;106:107015. PMID 32179503
76: Sager G, Vatansever Z, Batu U, Çağ Y, Akin Y. Neuropsychiatric comorbidities in genetic/idiopathic generalized epilepsies and their effects on psychosocial outcomes. Epilepsy Behav 2021;124:108339. PMID 34600282
77: Sala-Padró J, Toledo M, Santamarina E, et al. Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy. Clin Neuropharmacol 2016;39(6):299-301. PMID 27438183
78: Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512-21. PMID 28276062
79: Schmidt D. Response to antiepileptic drugs and the rate of relapse after discontinuation in juvenile myoclonic epilepsy. In: Schmitz D, Sander T, editors. Juvenile Myoclonic Epilepsy: The Janz Syndrome. Philadelphia: Wrightson, Petersfield, 2000:111-20.
80: Seneviratne U, Cook M, D'Souza W. Focal abnormalities in idiopathic generalized epilepsy: a critical review of the literature. Epilepsia 2014;55(8):1157-69. PMID 24938654
81: Senf P, Schmitz B, Holtkamp M, Janz D. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology 2013;81(24):2128-33. PMID 24212391
82: Stevelink R, Al-Toma D, Jansen FE, et al. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis. EClinicalMedicine 2022;53:101732. PMID 36467455
83: Stevelink R, Koeleman BPC, Sander JW, Jansen FE, Braun KPJ. Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors. Eur J Neurol 2019;26(6):856-64. PMID 30223294
84: Striano P, Nobile C. The genetic basis of juvenile myoclonic epilepsy. Lancet Neurol 2018;17(6):493-5. PMID 29778354
85: Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018;59(8):1549-56. PMID 29943451
86: Syvertsen M, Hellum MK, Hansen G, et al. Prevalence of juvenile myoclonic epilepsy in people <30 years of age-A population-based study in Norway. Epilepsia 2017;58(1):105-12. PMID 27861775
87: Tabrizi N, Zarvani A, Rezaei P, Cheraghmakani H, Alizadeh-Navaei R. Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial. Epilepsy Res 2019;157:106214. PMID 31627041
88: Thomas P, Genton P, Gélisse P, Medina M, Serafini A; Juvenile myoclonic epilepsy. In: Bureau M, Genton P, Dravet C, et al, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. Fifth edition with video. John Libbey Eurotext, 2012:305-28.
89: Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609-17. PMID 21652013
90: Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 2016;15:210-8. PMID 26655849
91: Turco F, Bonanni E, Milano C, et al. Prolonged epileptic discharges predict seizure recurrence in JME: Insights from prolonged ambulatory EEG. Epilepsia 2021;62(5):1184-92. PMID 33735449
92: Uchida CG, de Carvalho KC, Guaranha MS, et al. Phenotyping juvenile myoclonic epilepsy: praxis induction as a biomarker of unfavorable prognosis. Seizure 2015;32:62-8. PMID 26552565
93: Vollmar C, O'Muircheartaigh J, Symms MR, et al. Altered microstructural connectivity in juvenile myoclonic epilepsy: the missing link. Neurology 2012;78(20):1555-9. PMID 22551729
94: Vorderwülbecke BJ, Kowski AB, Kirschbaum A, et al. Long-term outcome in adolescent-onset generalized genetic epilepsies. Epilepsia 2017;58(7):1244-50. PMID 28464258
95: Wandschneider B, Centeno M, Vollmar C, et al. Motor co-activation in siblings of patients with juvenile myoclonic epilepsy: an imaging endophenotype? Brain 2014;137(Pt 9):2469-79. PMID 25001494
96: Wandschneider B, Hong SJ, Bernhardt BC, et al. Developmental MRI markers cosegregate juvenile patients with myoclonic epilepsy and their healthy siblings. Neurology 2019;93(13):e1272-80. PMID 31467252
97: Wandschneider B, Thompson PJ, Vollmar C, Koepp MJ. Frontal lobe function and structure in juvenile myoclonic epilepsy: a comprehensive review of neuropsychological and imaging data. Epilepsia 2012;53(12):2091-8. PMID 23106095
98: Wiggs KK, Rickert ME, Sujan AC, et al. Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. Neurology 2020;95(24):e3232-40. PMID 33115775
99: Winawer MR, Rabinowitz D, Pedley TA, Hauser WA, Ottman R. Genetic influences on myoclonic and absence seizures. Neurology 2003;61(11):1576-81. PMID 14663045

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Fernando Cendes MD PhD

Dr. Cendes of the University of Campinas - UNICAMP has no relevant financial relationships to disclose.
See Profile

Editor

Jerome Engel Jr MD PhD

Dr. Engel of the David Geffen School of Medicine at the University of California, Los Angeles, has no relevant financial relationships to disclose.
See Profile

Former Authors

Jerome Engel Jr MD PhD
Peter Wolf MD

Patient Profile

Age range of presentation: 6 to 18 years
Sex preponderance: Female > male
Heredity: heredity may be a factor

complex pattern of inheritance
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Juvenile myoclonic epilepsy: G40.3
ICD-11: Juvenile myoclonic epilepsy: 8A61.30
OMIM: Juvenile myoclonic epilepsy: #607628

Generalized epilepsy with febrile seizures plus, type 5, susceptibility to, included; GEFSP5, included: #613060

Epilepsy, idiopathic generalized, susceptibility to, 9; EIG9: #607682

Epilepsy, juvenile myoclonic, susceptibility to, 6, included; EJM6, included: #607682

Epilepsy, juvenile myoclonic, susceptibility to, 9; EJM9: %614280

Epilepsy, idiopathic generalized, susceptibility to, 11; EIG11: #607628

Epilepsy, idiopathic generalized, susceptibility to, 2, included; EJA2, included: #607628

Epilepsy, juvenile myoclonic, susceptibility to, 8, included; EJM8, included: #607628

Myoclonic epilepsy, juvenile, susceptibility to, 4; EJM4: %611364

Epilepsy, juvenile myoclonic, susceptibility to, 5, included; EJM5, included: #611136

Epilepsy, childhood absence, susceptibility to, 4, included; ECA4, included: #611136

Myoclonic epilepsy, juvenile, susceptibility to, 3; EJM3: %608816

Epilepsy, myoclonic juvenile; EJM: #254770

Epilepsy, juvenile myoclonic, susceptibility to, 10; EJM10: #617924

Epilepsy, idiopathic generalized, susceptibility to, 7; EIG7: %604827

Myoclonic epilepsy, juvenile, 2, included; EJM2, included: %604827

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Juvenile myoclonic epilepsy

Associated Disorders

Juvenile absence epilepsy
Generalized tonic-clonic seizures alone (formerly known as generalized tonic–clonic seizures on awakening)
Epilepsy with eyelid myoclonia syndrome
Myoclonic absence

Differential Diagnosis

Generalized tonic-clonic seizures alone (formerly known as generalized tonic–clonic seizures on awakening)
Juvenile absence epilepsy
Absence epilepsies
Lennox-Gastaut syndrome
Epilepsy with myoclonic-astatic seizures
- Epilepsy with myoclonic absences
- Postanoxic myoclonus
- Progressive myoclonic epilepsies

Also Relevant

Epilepsy
Generalized onset tonic-clonic seizures
Juvenile absence epilepsy
Lamotrigine
Levetiracetam
- Myoclonus
- Sleep disorders
- Topiramate
- Valproic acid

Juvenile myoclonic epilepsy (JME) …

Juvenile myoclonic epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Photosensitive occipital lobe epilepsy

Breath-holding spells

Intermittent explosive disorder

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Juvenile myoclonic epilepsy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Photosensitive occipital lobe epilepsy

Breath-holding spells

Intermittent explosive disorder

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

This is an article preview.
Start a Free Account
to access the full version.